Last $104.02 USD
Change Today +0.70 / 0.68%
Volume 1.4M
EW On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Open
$103.74
Previous Close
$103.32
Day High
$104.66
Day Low
$103.24
52 Week High
09/19/14 - $104.66
52 Week Low
12/13/13 - $60.62
Market Cap
11.0B
Average Volume 10 Days
925.8K
EPS TTM
$2.62
Shares Outstanding
106.0M
EX-Date
--
P/E TM
39.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for EDWARDS LIFESCIENCES CORP (EW)

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers surgical heart valve therapy products, such as tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial valves from biologically inert animal tissue. Its surgical heart valve therapy products include Carpentier-Edwards PERIMOUNT pericardial valve that comprise PERIMOUNT Magna Ease valves for aortic and mitral replacement; ThruPort systems that enable minimal incision valve surgery; and protection cannulae that is used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. The company also provides transcatheter heart valves portfolio that includes technologies designed to treat heart valve disease using catheter-based approaches, as well as critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; VolumeView sensor-catheters; FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for fluid optimization; and EV1000 clinical monitoring platform, which displays a patient's physiologic status. Its critical care products also include disposable pressure monitoring devices and closed blood sampling systems to help protect patients and clinicians from the risk of infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as balloon-tipped, catheter-based embolectomy products, surgical clips, and clamps. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

8,600 Employees
Last Reported Date: 02/28/14
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $879.8K
Corporate Vice President of Europe, Middle Ea...
Total Annual Compensation: $607.8K
Corporate Vice President of Critical Care & V...
Total Annual Compensation: $472.4K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $440.6K
Compensation as of Fiscal Year 2013.

edwards lifesciences corp (EW) Key Developments

Novation Enters into First Sole-Source Heart Valve Agreement with Edwards Lifesciences

Novation and Edwards Lifesciences Corporation announced they have entered into a three-year, sole-source strategic relationship that provides heart valve therapies to the more than 100,000 members and affiliates of VHA, UHC, Children's Hospital Association and Provista. The new agreement with Edwards for its heart valve product portfolio enables Novation to enter the heart valve category for the first time, and expands on the previous relationship between the companies for critical care technologies.

Edwards Lifesciences Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014 and Full Year 2014; Appoints Martyn Thomas as Vice President of Medical Affairs for Transcatheter Heart Valves

Edwards Lifesciences Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net income for the quarter ended June 30, 2014 of $547.0 million, or $5.09 per diluted share, and non-GAAP net income of $94.0 million, or $0.88 per diluted share, compared to net income for the same period a year earlier of $93.3 million, or $0.81 per diluted share, and non-GAAP net income was $96.7 million, or $0.84 per diluted share. Net sales for the quarter ended June 30, 2014 increased 11.2% to $575.1 million compared to $517.2 million for the same period last year. Underlying sales grew 10.5%. U.S. and international segment sales for the second quarter were $242.0 million and $333.1 million, respectively. Income before provision for income taxes was $813.2 million against $120.5 million a year ago. Net cash provided by operating activities was $778.0 million against $128.1 million a year ago. Capital expenditures were $16.0 million against $29.5 million a year ago. Non-GAAP free cash flow was $73.4 million against $98.6 million a year ago. For the six months, the company reported net income for the six months ended June 30, 2014 of $607.3 million, or $5.63 per diluted share, and non-GAAP net income of $176.1 million, or $1.63 per diluted share, compared to net income for the same period a year earlier of $237.2 million, or $2.05 per diluted share, and non-GAAP net income was $183.4 million, or $1.59 per diluted share. Net sales for the first six months of 2014 increased 8.2% to $1,097.5 million, compared to $1,013.9 million a year ago. Sales growth was 9.2% on an underlying basis. Income before provision for income taxes was $890.5 million against $311.1 million a year ago. Net cash provided by operating activities was $916.9 million against $229.2 million a year ago. Capital expenditures were $30.3 million against $66.3 million a year ago. Non-GAAP free cash flow was $198.0 million against $105.6 million a year ago. The company provided earnings guidance for the third quarter of 2014 and full year 2014. For the third quarter of 2014, the company expects total sales to be between $530 million and $570 million, and diluted earnings per share, excluding special items, to be between $0.66 and $0.72. For the full year, the company now expects full year 2014 total sales at the high end of its previous $2.05 billion to $2.25 billion range. The company also raised its guidance for full year 2014 diluted earnings per share, excluding special items, to a range of $3.24 to $3.34. The company is confident in its outlook for continued strong organic sales growth, reflecting its focused innovation strategy, and its commitment to helping patients. The company also announced that it has appointed Dr. Martyn Thomas to the newly created position of vice president of medical affairs for transcatheter heart valves. He is currently the clinical director of cardiovascular services at St. Thomas' Hospital in London and a global leader in transcatheter heart valve research.

Edwards Lifesciences Mulls Acquisitions

Edwards Lifesciences Corp. (NYSE:EW) is looking for acquisitions. Mike Mussallem, Chief Executive Officer of Edwards Lifesciences said, "We remain open to considering acquisitions to supplement our existing portfolio".

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $104.02 USD +0.70

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $147.23 USD +0.35
Endo International PLC $67.70 USD +0.76
Hologic Inc $24.14 USD -0.43
Mettler-Toledo International Inc $265.36 USD -2.68
Cooper Cos Inc/The $159.15 USD +2.14
View Industry Companies
 

Industry Analysis

EW

Industry Average

Valuation EW Industry Range
Price/Earnings 15.0x
Price/Sales 5.2x
Price/Book 5.8x
Price/Cash Flow 14.5x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit www.edwards.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.